Pharming Group NV: Pharming announces publication of data fr

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The

Related Keywords

United States , Netherlands , United Kingdom , London , City Of , Amsterdam , Noord Holland , America , American , Ethan Metelenis , Heather Robertson , Michael Levitan , Dan Caley , Anurag Relan , Vicki Modell , Linkedin , Vp Investor Relations Corporate Communications , Nasdaq , Exchange Commission , American Society Of Hematology , Prnewswire Pharming Groupnv , Pharming Group , Lifespring Life Sciences Communication , Jeffrey Modell Foundation , Investor Relations Corporate Communications , American Society , Inhibitor Leniolisib , Chief Medical Officer , Activated Phosphoinositide , North America , Middle East , Annual Report , Allergy Clin , Rev Allergy , Investor Relations , Corporate Communications , Spring Life Sciences Communication , Pharming , Group , Nnounces , Publication , Data , Rom , Hase , Study , Eniolisib , Patients , Pds , Flood ,